Pancrelipase vs Rituximab

## Pancrelipase vs Rituximab: Overview

This comparison examines the pharmacological differences between **Pancrelipase** and **Rituximab**.

## Mechanism of Action

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Pancrelipase — N/A; Rituximab — 22 days.

## Chemical Properties

**Type**: Pancrelipase — Enzyme; Rituximab — Antibody.